1. Prevention and Treatment of Prostate Cancer: Technologies and
Global Markets
Report Details:
Published:January 2013
No. of Pages: 235
Price: Single User License – US$5450
REPORT HIGHLIGHTS
This report provide:
•An overview of the market for the prevention and treatment of prostate cancer, with coverage of
the mechanisms of disease development, detection and diagnosis, and anticancer agents
•Analyses of global market trends, with data from 2010, 2011 and 2012, and projections of
compound annual growth rates (CAGRs) through 2017
•Discussion of risk factors, natural history, epidemiology, and the genetics of prostate cancer
•Examinations of prostate-specific antigen (PSA) screening, including the causes of PSA changes,
PSA thresholds, and controversies over the screening
•Coverage of emerging therapies, including combination therapy, therapeutic vaccines, inhibitors
of kinase signaling pathways, proteasome inhibitors, angiogenesis inhibitors, and
immunotherapeutic agents
•Evaluation of prostate cancer treatment products by geography, race, and category
•Breakdown of the industry structure, including market shares, trends in price and price
performance, and factors influencing demand
•Comprehensive company profiles.
STUDY GOALS AND OBJECTIVES
This report “Prevention and Treatment of Prostate Cancer: Technologies and Global Markets”
provides an overview of the current and potential global market for prostate cancer treatments and
testing technologies. The key objective is to present a comprehensive analysis of the current state
of prostate cancer therapy and technology, utilization of the various therapeutic and diagnostic
modalities to prevent and treat prostate cancer. The report's focus is on prostate cancer treatment
strategies such as hormone therapy, chemotherapy, radiotherapy and immunotherapy, and other
treatment modalities and testing and screening methods. The report also includes an overview on
prostate cancer staging, diagnostic strategies and technologies. Important trends in the field of
prostate cancer research and development have been reviewed in this report, and sales forecasts
by treatment and screening categories are provided from 2012 through 2017. Issues and trends
addressed in this report are based on information from industry sources, regulatory and healthcare
policies, demographics and other factors that directly affect the prostate cancer market.

2. REASONS FOR DOING THIS STUDY
This study was conducted to provide detailed information regarding screening, testing and
treatment options for prostate cancer. There is an increasing need for new and innovative
technologies. This industry is experiencing growth. The use of new drug delivery technologies for
prostate cancer has increased in the past few years. This study looks at most types of treatment
strategies for the clinical management of prostate cancer.
This BCC market research report will increase the awareness of current and emerging drugs and
technologies for prostate cancer, including hormone therapy, chemotherapy, radiation therapy,
surgical therapy, immunotherapy and also nutrition therapy.
SCOPE OF THE STUDY
The scope of this study is testing, screening technology and also therapeutics markets for prostate
cancer. The report also includes the regulatory environment, current technologies, new
technologies, prostate cancer incidence, market projections and market share, along with latest
trends and new developments.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this report.
Secondary sources include books, newspapers, trade journals, white papers, industry portals,
government agencies, trade associations, monitoring industry news and developments, and
through access to paid and free databases. The base year of the report is 2012, with forecast data
provided through 2017. Historical, base year and forecast data are provided for each market
segment of this report. The report provides a comprehensive review of prostate cancer, incidence
and development of the disease, drugs currently being used and diagnostic technologies. The
report also reviews technological developments, product innovations/ introductions and recent
strategic industry activity of major players across various product categories. Growth rates, global
incidence and projections are determined through a compilation of data, including past trends,
future trends, demographics, incidence, mortality, products in R&D and current product growth,
etc. Forecasts and projections were based on estimates such as the current trends, potential
users, mergers and acquisitions, and market trends.
A comprehensive and exhaustive search of the literature on prostate cancer assay development
and already-marketed products, global incidence and latest drug developments was conducted.
These secondary sources included scientific-related journals and articles, textbooks, press
releases, marketing literature, other product/promotional literature, annual reports, security analyst
reports and other publications. A patent search and analysis were also conducted. Some informal
interviews were also conducted with experts and personnel in this area at biotech and
pharmaceutical companies. Other resources included academics, technology and consulting
companies.
INFORMATION SOURCES
Many companies within the industry were surveyed to obtain data for this study. Included were
manufacturers, end users of products, which included pharmaceutical and biotechnical industries,
research institutes, etc. Data were gathered from various industry sources. BCC spoke with
officials within the industry, consulted newsletters, company literature, product literature and a host
of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by

3. key terminology were completed. In addition, data were compiled from current financial, trade and
government sources.
Get your copy of this report @
http://www.reportsnreports.com/reports/213066-prevention-and-treatment-of-prostate-cancer-technologies-and-
global-markets.html
Major points covered in Table of Contents of this report include
TABLE OF CONTENTS
Chapter - 1: INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THIS STUDY
INTENDED AUDIENCE
SCOPE OF THE STUDY
METHODOLOGY
INFORMATION SOURCES
ABOUT THE AUTHOR
RELATED BCC REPORTS
BCC ON-LINE SERVICES
DISCLAIMER
Chapter - 2: SUMMARY
Table Summary: GLOBAL PROSTATE CANCER MARKET, THROUGH 2017
Figure Summary: GLOBAL PROSTATE CANCER MARKET, 2010 - 2017
Chapter - 3: OVERVIEW
INTRODUCTION
U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS
Table 1: U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS, 2008
BIOLOGY OF PROSTATE CANCER
PROSTATE GLAND
PROSTATE GLAND FUNCTION
GROWTH OF THE PROSTATE GLAND
TYPES OF PROSTATE CANCER
PRECANCEROUS CONDITIONS OF THE PROSTATE
Prostatic Intraepithelial Neoplasia (PIN)
Proliferative Inflammatory Atrophy (PIA)
PROSTATE CANCER DEVELOPMENT AND AGING
MECHANISMS OF DISEASE DEVELOPMENT PATHOPHYSIOLOGY
FAMILY HISTORY
ENVIRONMENTAL FACTORS
EPIDEMIOLOGY AND RISK FACTORS
HORMONES
GROWTH FACTORS
Table 2: GROWTH FACTORS IMPLICATED IN PROSTATE CANCER

4. GENETICS
Table 3: PROPOSED PROSTATE CANCER SUSCEPTIBILITY LOCI
MOLECULAR MECHANISMS OF PROSTATE CANCER
Table 4: IMPORTANT GENES IN THE DEVELOPMENT OF PROSTATE CANCER
THE ANDROGEN RECEPTOR
PTEN
P53
GSTP GENES
Table 5: MUTATED GENES AND ABNORMAL PROTEIN EXPRESSION
PROSTATE-SPECIFIC ANTIGEN
CAVEOLIN-1
EMSY
AMACR
KLF6
NBS1
CHEK2
MISMATCH REPAIR GENES
HOXB13
BRCA1 AND BRCA2
HEREDITARY PROSTATE CANCER
PROSTATE CANCER PREVENTION AND TREATMENT
CONCLUSIONS
Chapter - 4: PROSTATE CANCER
DETECTION AND DIAGNOSIS
DIAGNOSIS
How is Prostate Cancer Diagnosed?
Tests to Diagnose Prostate Cancer
SCREENING, DIAGNOSIS AND MANAGEMENT OF PROSTATE CANCER
GUIDELINES FOR PROSTATE CANCER SCREENING
RECOMMENDATIONS FOR PROSTATE CANCER EARLY DETECTION
NEW PROSTATE CANCER SCREENING GUIDELINES
RECENT DEVELOPMENTS
PROSTATE CANCER SCREENING
STAGING AND GRADING OF PROSTATE CANCER
DIAGNOSTIC BIOPSY
TEST FOR METASTASIS
NEW METHODS IN DEVELOPMENT
IMAGING STRATEGIES FOR DIAGNOSIS OF PROSTATE CANCER
PROSTATE CANCER PROGNOSIS AND OUTCOMES PREDICTIONS
CONCLUSIONS
Chapter - 5: PROSTATE CANCER SCREENING AND DIAGNOSIS
DIAGNOSTIC PRODUCTS

5. Table 13: PROSTATE CANCER: DIAGNOSIS AND TREATMENT STRATEGY
PROSTATE CANCER SCREENING, DIAGNOSIS AND PROGNOSIS
PSA TESTS
New Types of PSA Tests
Percent-free PSA
PSA Velocity
PSA Density
Age-Specific PSA Ranges
THE DRE
PROSTATE ULTRASOUND AND BIOPSY
IMAGING TECHNOLOGIES FOR PROSTATE CANCER
Computerized Tomography
Magnetic Resonance Imaging
Endorectal MRI Technology
Magnetic Resonance Spectroscopic Imaging
Proton Radiation Therapy
High Intensity Focused Ultrasound
Table 14: PROSTATE CANCER TESTS
CONCLUSIONS
Chapter - 6: PROSTATE CANCER: THERAPEUTIC INTERVENTIONS
TREATMENT PLAN
TREATMENT OPTIONS
Watchful Waiting or Active Surveillance
Table 16: FACTORS FOR PROSTATE CANCER TREATMENT PLANNING
Table 17: GUIDE TO PROSTATE CANCER DIAGNOSIS AND MANAGEMENT
SURGERY
Radical Prostatectomy
Table 18: TYPES OF SURGERY
SECONDARY THERAPY
Counseling about Postoperative Erectile Dysfunction
Table 19: ADVANTAGES AND DISADVANTAGES OF RADICAL PROSTATECTOMY
RADIOTHERAPY
INTERSTITIAL BRACHYTHERAPY FOR LOW-RISK CANCERS
Table 20: ADVANTAGES AND DISADVANTAGES OF INTERSTITIAL BRACHYTHERAPY
EXTERNAL BEAM RADIOTHERAPY
Table 21: ADVANTAGES AND DISADVANTAGES OF EXTERNAL BEAM RADIOTHERAPY
COMBINED RADIATION THERAPY
CRYOTHERAPY
Table 22: ADVANTAGES AND DISADVANTAGES OF CRYOTHERAPY
HIGH-INTENSITY FOCUSED ULTRASOUND
Table 23: ADVANTAGES AND DISADVANTAGES OF ULTRASOUND
FOCAL ABLATION

6. HORMONE THERAPY
Table 24: HORMONE THERAPY
ANDROGEN DEPRIVATION, AN ADJUVANT THERAPY
Post-treatment Monitoring
CHEMOPREVENTION AND CHEMOTHERAPY
IMMUNOTHERAPY
NUTRITIONAL THERAPY
ERECTILE DYSFUNCTION
EMERGING THERAPIES
Combination Therapy
Therapeutic Vaccines
New Drugs for Hormone-Resistance Prostate Cancer
Inhibitors of Kinase Signaling Pathways
Proteasome Inhibitors
Angiogenesis Inhibitors
TREATMENT STRATEGIES FOR PROSTATE CANCER BY STAGE
Table 25: STAGE I PROSTATE CANCER
Table 26: STAGE II PROSTATE CANCER
Table 27: STAGE III PROSTATE CANCER
Table 28: STAGE IV PROSTATE CANCER
Table 15: TREATMENT OPTIONS FOR PROSTATE CANCER
Chapter - 7: PROSTATE CANCER THERAPEUTICS IN THE GLOBAL MARKET
WHAT IS CANCER?
Table 29: THERAPEUTICS FOR PROSTATE CANCER TREATMENT
DRUGS APPROVED FOR PROSTATE CANCER
LUPRON (LEUPROLIDE ACETATE)
TAXOTERE (DOCETAXEL)
JEVTANA (CABAZITAXEL)
ZYTIGA (ABIRATERONE ACETATE)
PROVENGE (SIPULEUCEL-T)
XGEVA (DENOSUMAB)
Table 31: COMMON DRUGS FOR TREATMENT OF PROSTATE CANCER
AVODART (DUTASTERIDE)
Table 30: APPROVED FDA PROSTATE CANCER DRUGS
DRUG DESCRIPTIONS
CASODEX (BICALUTAMIDE)
Clinical Pharmacology
Clinical Studies
Figure 1: STRUCTURE OF CASODEX
ZOLADEX (GOSERELIN ACETATE)
Clinical Pharmacology
Clinical Studies

7. Post-Marketing Studies
Figure 2: CHEMICAL STRUCTURE OF ZOLADEX
ELIGARD (LEUPROLIDE)
Clinical Pharmacology
Clinical Studies
Post-Marketing Studies
Figure 3: CHEMICAL STRUCTURE OF ELIGARD
NILANDRON (NILUTAMIDE)
Clinical Pharmacology
Clinical Studies
Post-Marketing Studies
Figure 4: CHEMICAL STRUCTURE OF NILANDRON
FLUTAMIDE
Clinical Pharmacology
Clinical Studies
Post Marketing Studies
Figure 5: CHEMICAL STRUCTURE OF FLUTAMIDE
TRIPTORELIN (TRELSTAR)
Clinical Pharmacology
Clinical Trials
Post-Marketing Studies
Figure 6: CHEMICAL STRUCTURE OF TRELSTAR
ESTRAMUSTINE (EMCYT)
Clinical Pharmacology
Figure 7: CHEMICAL STRUCTURE OF ESTRAMUSTINE
FIRMAGON (DEGARELIX ACETATE)
Clinical Pharmacology
Clinical Studies
Figure 8: CHEMICAL STRUCTURE OF FIRMAGON
TAXOTERE (DOCETAXEL)
Clinical Pharmacology
Clinical Studies
Post-Marketing Studies
Figure 9: CHEMICAL STRUCTURE OF DOCETAXEL
JEVTANA (CABAZITAXEL)
Clinical Pharmacology
Clinical Studies
Figure 10: CHEMICAL STRUCTURE OF JEVTANA
MITOXANTRONE (NOVANTRONE)
VINORELBINE (NAVELBINE)
ZYTIGA (ABIRATERONE ACETATE)
Clinical Pharmacology

8. Clinical Studies
Figure 11: CHEMICAL STRUCTURE OF ZYTIGA
PROVENGE (SIPULEUCEL-T)
Clinical Pharmacology
Clinical Studies
OTHER THERAPEUTIC AGENTS
Table 32: THERAPEUTIC AGENTS FOR PROSTATE CANCER UNDER CLINICAL
DEVELOPMENT
Chapter - 8: GLOBAL BURDEN OF CANCER
GLOBAL PROSTATE CANCER STATISTICS
PROSTATE CANCER MORTALITY
Table 35: GLOBAL ESTIMATED PROSTATE CANCER DEATHS: AGE-STANDARDIZED
MORTALITY RATES PER 100,000 MEN, 2008
Figure 14: GLOBAL ESTIMATED PROSTATE CANCER DEATHS: AGE-STANDARDIZED
MORTALITY RATES PER 100,000 MEN, 2008
Table 34: PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008
Figure 13: PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008
PROSTATE CANCER BURDEN GLOBALLY
Table 36: GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER, 2008-2030
Figure 15: GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER 2008-2030
PROSTATE CANCER IN THE U.S.
PROSTATE CANCER MORTALITY RATES IN THE U.S.
Table 41: MORTALITY RATES BY RACE IN THE U.S., 2005-2009
PROSTATE CANCER AND AFRICAN AMERICAN MEN
Table 42: DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS
FOR MALES OF ALL RACES, 2002-2008
Table 43: RELATIVE SURVIVAL RATE FOR PROSTATE CANCER PATIENTS
SURVIVAL RATES BY STAGE
Table 44: FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT THE TIME OF DIAGNOSIS
Table 37: PROSTATE CANCER CASES AND DEATHS IN THE U.S., 2008 - 2011
Figure 16: PROSTATE CANCER CASES AND DEATHS IN THE U.S., 2008 - 2011
Table 38: ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012 - 2030
Figure 17: ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012 - 2030
Table 39: INCIDENCE RATES BY RACE IN THE U.S., 2005-2009
Table 40: ESTIMATED NEW PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030
Figure 18: ESTIMATED NEW PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030
PROSTATE CANCER AND CANADA
Table 45: ESTIMATED PROSTATE CANCER IN CANADA, 2012
PROSTATE CANCER AND EUROPE
PROSTATE CANCER AND UNITED KINGDOM
Table 47: PROSTATE CANCER DEATHS IN THE U.K., RATE PER 100,000 PEOPLE, 2010
Figure 20: PROSTATE CANCER DEATHS IN THE U.K.: RATE PER 100,000 PEOPLE, 2010

9. Table 46: ESTIMATED PROSTATE CANCER MORTALITY IN EU27 COUNTRIES: AGE-
STANDARDIZED MORTALITY RATES PER 100,000 MEN, 2008
Figure 19: ESTIMATED PROSTATE CANCER MORTALITY IN EU27 COUNTRIES: AGE-
STANDARDIZED MORTALITY RATES PER 100,000 MEN, 2008
PROSTATE CANCER IN ASIA
OTHER NATIONS
JAMAICA
AUSTRALIA
CONCLUSIONS
Table 33: GLOBAL CANCER INCIDENCE ESTIMATES, 2008
Figure 12: GLOBAL CANCER INCIDENCE ESTIMATES, 2008
Chapter - 9: PROSTATE CANCER AND DIAGNOSTIC MARKET
SCREENING TESTS
PSA TESTING: YES OR NO CONTROVERSY
PROSTATE CANCER MARKET SIZE
PROSTATE CANCER SCREENING MARKET
PSA Test and Market
Table 49: GLOBAL PSA TEST SALES AND FORECAST, THROUGH 2017
Figure 21: GLOBAL PSA TEST SALES AND FORECAST, 2010 - 2017
Table 50: U.S. PSA TEST SALES AND FORECAST, THROUGH 2017
Figure 22: U.S. PSA TEST SALES AND FORECAST, 2011 - 2017
Table 51: EUROPEAN PSA TEST SALES AND FORECAST, THROUGH 2017
Figure 23: EUROPEAN PSA TEST SALES AND FORECAST, 2011 - 2017
Table 52: CANADIAN PSA TEST SALES AND FORECAST, THROUGH 2017
Figure 24: CANADIAN PSA TEST SALES AND FORECAST, 2011 - 2017
Table 53: OTHER COUNTRIES: PSA TEST SALES AND FORECAST, THROUGH 2017
Figure 25: OTHER COUNTRIES: PSA TEST SALES AND FORECAST, 2010 - 2017
DRE MARKET
Table 54: GLOBAL DIGITAL RECTAL EXAMINATION SALES AND FORECAST, THROUGH
2017
Figure 26: GLOBAL DIGITAL RECTAL EXAMINATION SALES AND FORECAST, 2010 - 2017
Table 55: U.S. DIGITAL RECTAL EXAMINATION SALES AND FORECAST, THROUGH 2017
Figure 27: U.S. DIGITAL RECTAL EXAMINATION SALES AND FORECAST, 2010 - 2017
Table 56: DIGITAL RECTAL EXAMINATION SALES AND FORECAST FOR THE REST OF THE
WORLD (EXCLUDING THE U.S.), THROUGH 2017
Figure 28: DIGITAL RECTAL EXAMINATION SALES AND FORECAST FOR THE REST OF THE
WORLD (EXCLUDING THE U.S.), 2010 - 2017
MARKET FOR PROSTATE BIOPSY
PSA and DRE Manufacturers and Market
Table 62: MANUFACTURERS/SUPPLIERS OF PROSTATE CANCER DIAGNOSTICS MARKET
SHARE, 2012
Table 57: GLOBAL COST OF PROSTATE BIOPSIES, THROUGH 2017

10. Figure 29: GLOBAL COST OF PROSTATE BIOPSIES, 2010 - 2017
Table 58: U.S. COST OF PROSTATE BIOPSIES, THROUGH 2017
Figure 30: U.S. COST OF PROSTATE BIOPSIES, 2010 - 2017
Table 59: COST OF PROSTATE BIOPSIES IN THE REST OF THE WORLD (EXCLUDING THE
U.S.), THROUGH 2017
Figure 31: COST OF PROSTATE BIOPSIES IN THE REST OF THE WORLD (EXCLUDING THE
U.S.), 2010 - 2017
Table 60: GLOBAL COSTS AND FORECAST FOR PROSTATE BIOPSIES BY REGION,
THROUGH 2017
Figure 32: GLOBAL COSTS AND FORECAST FOR PROSTATE BIOPSIES BY REGION, 2010 -
2017
Table 61: GLOBAL PROSTATE CANCER SCREENING SALES AND FORECAST, THROUGH
2017
Figure 33: GLOBAL PROSTATE CANCER SCREENING SALES AND FORECAST, 2010 - 2017
NEW TESTS ON THE HORIZON
Myriad Genetics
Prostate Health Index
AnalizaDx
MDxHealth and PLUS Diagnostics
Opko Health
Table 63: LIST OF AVAILABLE PROSTATE NOMOGRAMS
Genomic Health
MDxHealth
Caris Life Sciences
Gen-Probe
Table 48: TYPE OF DIAGNOSTIC TESTS
PROSTATE CANCER DIAGNOSTIC IMAGING MARKET
Table 64: GLOBAL MARKET SIZE FOR IMAGING TECHNOLOGIES, THROUGH 2017
Figure 34: GLOBAL MARKET SIZE FOR IMAGING TECHNOLOGIES, 2010 - 2017
Table 65: MANUFACTURERS/SUPPLIERS OF PROSTATE CANCER IMAGING DEVICES
MARKET SHARE, 2012
Chapter - 10: THE PROSTATE TREATMENT MARKET
TREATMENT PLAN FOR PROSTATE CANCER
PROSTATE CANCER THERAPIES: THREE LEADING PROSTATE CANCER THERAPIES
Table 66: COST OF THE THREE LEADING PROSTATE CANCER THERAPIES, 2012
PROSTATE CANCER SURGERY AND RADIOTHERAPY MARKET
Table 67: SURGICAL DEVICE COMPANIES: KEY PLAYERS
Table 68: GLOBAL PROSTATE CANCER THERAPY MARKET: SALES AND FORECAST,
THROUGH 2017
Figure 35: GLOBAL PROSTATE CANCER THERAPY MARKET: SALES AND FORECAST, 2010
- 2017
RADIOTHERAPY MARKET

11. Table 69: GLOBAL MARKET FOR EXTERNAL BEAM RADIATION THERAPY: FORECAST AND
SALES, 2010 - 2017
Figure 36: GLOBAL MARKET FOR EXTERNAL BEAM RADIATION THERAPY: FORECAST AND
SALES, 2010 - 2017
PROSTATE CANCER SURGICAL DEVICE MARKET
BRACHYTHERAPY MARKET
Table 70: GLOBAL BRACHYTHERAPY MARKET: FORECAST AND SALES, THROUGH 2017
Figure 37: GLOBAL BRACHYTHERAPY MARKET: FORECAST AND SALES, 2010 - 2017
PROSTATECTOMY MARKET
Table 71: GLOBAL INCIDENCE OF PROSTATE CANCER, THROUGH 2017
Figure 38: GLOBAL INCIDENCE OF PROSTATE CANCER, 2008 - 2017
Table 72: GLOBAL CASES OF PROSTATE SURGERIES PERFORMED PER YEAR, 2009 - 2017
Figure 39: GLOBAL CASES OF PROSTATE SURGERIES PERFORMED PER YEAR, 2009 -
2017
Table 73: GLOBAL MARKET FOR PROSTATE SURGERIES: SALES AND FORECAST,
THROUGH 2017
Figure 40: GLOBAL MARKET FOR PROSTATE SURGERIES: SALES AND FORECAST, 2009 -
2017
Table 74: GLOBAL CASES OF ROBOTIC PROSTATECTOMIES PERFORMED PER YEAR,
2009 - 2017
Figure 41: GLOBAL MARKET FOR PROSTATE SURGERIES: SALES AND FORECAST, 2009-
2017
Table 75: GLOBAL MARKET FOR ROBOTIC PROSTATECTOMY: SALES AND FORECAST,
THROUGH 2017
Figure 42: GLOBAL MARKET FOR ROBOTIC PROSTATECTOMY: SALES AND FORECAST,
2009 - 2017
Table 76: GLOBAL MARKET FOR OPEN PROSTATECTOMY: SURGERIES PER YEAR,
THROUGH 2017
Figure 43: GLOBAL MARKET FOR OPEN PROSTATECTOMY: SURGERIES PER YEAR, 2009 -
2017
Table 77: GLOBAL MARKET FOR OPEN PROSTATECTOMY: SALES AND FORECAST,
THROUGH 2017
Figure 44: GLOBAL MARKET FOR OPEN PROSTATECTOMY: SALES AND FORECAST, 2009 -
2017
U.S. UROLOGICAL MARKET
U.S. Market for Brachytherapy Devices
Table 79: U.S. BRACHYTHERAPY MARKET: SALES AND FORECAST, THROUGH 2017
Figure 46: U.S. BRACHYTHERAPY MARKET: SALES AND FORECAST, 2010 - 2017
Table 80: PROSTATE CANCER INCIDENCE IN THE U.S., 2008 - 2017
Figure 47: PROSTATE CANCER INCIDENCE IN THE U.S., 2008 - 2017
Table 81: U.S. ROBOTIC PROSTATECTOMY MARKET: SALES AND FORECAST, THROUGH
2017

12. Figure 48: U.S. ROBOTIC PROSTATECTOMY MARKET: SALES AND FORECAST, 2009 - 2017
Table 82: PROSTATECTOMY SURGERIES PERFORMED EACH YEAR IN THE U.S., 2009 -
2017
Figure 49: PROSTATECTOMY SURGERIES PERFORMED EACH YEAR IN THE U.S., 2009 -
2017
Table 83: U.S. PROSTATECTOMY MARKET: SALES AND FORECAST, THROUGH 2017
Figure 50: U.S. PROSTATECTOMY MARKET: SALES AND FORECAST, 2009 - 2017
Table 78: U.S. UROLOGICAL DEVICE MARKET: SALES AND FORECAST, THROUGH 2017
Figure 45: U.S. UROLOGICAL DEVICE MARKET: SALES AND FORECAST, 2009 - 2017
PROSTATE CANCER DEVICE MARKET IN ASIA AND LATIN AMERICA
MARKET: PROSTATE CANCER DRUGS
GLOBAL ONCOLOGY THERAPEUTICS MARKET
New Approaches to Treat Prostate Cancer
Table 84: GLOBAL CANCER MARKET, THROUGH 2017
Figure 51: GLOBAL CANCER MARKET, 2010 - 2017
CYTOTOXIC THERAPIES MARKET
Table 85: GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017
Table 86: CYTOTOXIC THERAPIES MARKET INDICATIONS
Table 87: EXPIRY OF PATENTS ON MAJOR CYTOTOXIC DRUGS
Table 88: U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2017
Figure 52: U.S. CYTOTHERAPEUTICS MARKET, 2010 - 2017
Table 89: EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2017
Figure 53: EUROPEAN CYTOTHERAPEUTICS MARKET, 2010 - 2017
Table 90: JAPANESE CYTOTHERAPEUTICS MARKET, THROUGH 2017
Figure 54: JAPANESE CYTOTHERAPEUTICS MARKET, 2010 - 2017
Table 91: MAJOR CYTOTOXIC BRANDS SALES, 2011
PROSTATE CANCER INCIDENCE AND IMPACT ON MARKET
Prostate Cancer Market Size
Table 92: PROSTATE CANCER: DRUG PRODUCTS AND TREATMENT MARKET, THROUGH
2017
Figure 55: PROSTATE CANCER: DRUG PRODUCTS AND TREATMENT MARKET, 2010 - 2017
Cost of Prostate Cancer Therapy, Care and Management
CURRENT PROSTATE CANCER THERAPEUTICS
Table 93: PROSTATE CANCER DRUG MARKET, THROUGH 2017
Figure 56: PROSTATE CANCER DRUG MARKET, 2010 - 2017
Table 94: PROSTATE CANCER DRUG PRODUCTS BY TREATMENT CATEGORY, THROUGH
2017
Figure 57: PROSTATE CANCER DRUG PRODUCTS BY TREATMENT CATEGORY, 2010 - 2017
GENERIC PROSTATE CANCER DRUGS
NEWER THERAPIES ON THE MARKET
RECENT DRUG APPROVALS AND MARKET

13. Table 96: NEW DRUGS AND SALES FORECAST, 2017
Table 95: U.S. PROSTATE CANCER MARKET: PATIENTS AND TREATMENT STRATEGIES
PROSTATE CANCER: THERAPEUTIC DRUGS LANDSCAPE
MARKET FOR CHEMOTHERAPY
Table 98: GLOBAL PROSTATE CANCER CHEMOTHERAPY DRUGS
Table 99: GLOBAL CHEMOTHERAPY MARKET FOR PROSTATE CANCER SALES AND
FORECAST, THROUGH 2017
Figure 58: GLOBAL CHEMOTHERAPY MARKET FOR PROSTATE CANCER SALES AND
FORECAST, 2010 - 2017
MARKET FOR CHEMOTHERAPY DRUGS FOR PROSTATE CANCER
Taxotere/Docetaxel
Table 100: KEY CHEMOTHERAPEUTIC DRUGS FOR PROSTATE CANCER: SALES AND
FORECAST, 2010 - 2012
Cabazitaxel/Jevtana
Mitoxantrone (Novantrone)
Vinorelbine (Navelbine)
Estramustine (Emcyt)
MARKET FOR HORMONE THERAPY
Table 101: GLOBAL PROSTATE CANCER HORMONAL THERAPY DRUGS
Table 102: HORMONE THERAPY FOR PROSTATE CANCER SALES AND FORECAST,
THROUGH 2017
Figure 59: HORMONE THERAPY FOR PROSTATE CANCER SALES AND FORECAST, 2010 -
2017
Table 103: GENERICS: SALES AND FORECAST, THROUGH 2017
HORMONE THERAPY DRUGS
Casodex or Bicalutamide
Zytiga/Abiraterone
Table 105: ZYTIGA: SALES ESTIMATES FOR 2011 AND 2012
Figure 61: ZYTIGA: SALES ESTIMATES FOR 2011 AND 2012
Table 106: GLOBAL SALES AND FORECAST FOR ZYTIGA, 2011 - 2017
Figure 62: GLOBAL SALES AND FORECAST FOR ZYTIGA, 2011 - 2017
Xtandi or Enzalutamide
Flutamide
Table 107: GLOBAL MARKET FOR FLUTAMIDE, 2009 AND 2010
Nilutamide
Triptorelin
Table 108: GLOBAL MARKET FOR TRIPTORELIN, 2009 AND 2010
Leuprolide Acetate
Table 109: GLOBAL MARKET FOR LEUPROLIDE ACETATE, 2009 AND 2010
Zoladex
Table 110: GLOBAL MARKET FOR ZOLADEX: SALES AND FORECAST, 2009 - 2017
Figure 63: GLOBAL MARKET FOR ZOLADEX: SALES AND FORECAST, 2009 - 2017

14. Degarelix Acetate
MARKET FOR IMMUNOTHERAPY
Provenge
Table 112: PROVENGE ANNUAL SALES AND FORECAST, 2010 - 2017
Figure 65: PROVENGE ANNUAL SALES AND FORECAST, 2010 - 2017
Provenge and Future Growth
Provenge and Abiraterone Competition
Table 111: GLOBAL PROSTATE CANCER IMMUNOTHERAPY DRUG SALES AND FORECAST,
THROUGH 2017
Figure 64: GLOBAL PROSTATE CANCER IMMUNOTHERAPY DRUG SALES AND FORECAST,
2010 - 2017
PROSTATE CANCER CARE MARKET
Table 113: GLOBAL MARKET FOR PROSTATE CANCER BY REGION, THROUGH 2017
Figure 66: GLOBAL MARKET FOR PROSTATE CANCER BY REGION, 2012 AND 2017
Table 114: PROSTATE CANCER CARE MARKET IN EUROPE, THROUGH 2017
Figure 67: PROSTATE CANCER CARE MARKET IN EUROPE, 2012 AND 2017
Table 115: U.S. PROSTATE CANCER CARE MARKET, THROUGH 2017
Figure 68: U.S. PROSTATE CANCER CARE MARKET, 2012 AND 2017
Table 116: PROSTATE CANCER CARE MARKET IN CANADA, THROUGH 2017
Figure 69: PROSTATE CANCER CARE MARKET IN CANADA, 2012 AND 2017
Table 97: GLOBAL SALES AND FORECAST: KEY PROSTATE CANCER DRUGS, 2010 - 2012
CONCLUSIONS
Table 117: GLOBAL PROSTATE CANCER MARKET: SALES AND FORECAST, THROUGH
2017
Figure 70: GLOBAL PROSTATE CANCER MARKET: SALES AND FORECAST, 2010 - 2017
Chapter - 11: EMERGING PROSTATE CANCER DRUGS
CABOZANTINIB
XGEVA
CUSTIRSEN
TASQUINIMOD
SPRYCEL
TAK-700
PROSTVAC
ALPHARADIN
AVODART
DCVAX-PROSTATE
CONCLUSIONS
Table 118: EMERGING PRODUCTS FOR PROSTATE CANCER
Chapter - 12: PROSTATE CANCER PATENTS
PROSTATE CANCER DRUG PATENTS EXPIRY
NEW PATENT APPLICATIONS
CZ BioMed Corp.

15. Adamis Pharmaceuticals
Antisense Therapeutics
Table 121: EXPIRY OF PATENTS ON MAJOR BRANDS
Table 122: LIST OF KEY DENDREON PATENTS AND PATENT APPLICATIONS
Table 119: PROSTATE CANCER PATENT TRENDS, 2002-2011
Table 120: PATENTS BY TREATMENT CATEGORY, 2002 - 2011
Chapter - 13: RESEARCH AND INNOVATIONS IN TECHNOLOGY
NEW THERAPEUTIC DEVELOPMENTS
ONCOGENEX
MEDIVATION
SPECTRUM PHARMACEUTICALS
NEW DEVELOPMENTS IN DIAGNOSTIC TESTING FOR PSA
GENOMIC HEALTH
NEW MRI TECHNOLOGY
HIGH-INTENSITY FOCUSED ULTRASOUND
CONCLUSIONS
Chapter - 14: SELECTED COMPANY PROFILES
ABBOTT LABORATORIES
ACTIVE BIOTECH AB
ALGETA
AMGEN
ASTELLAS PHARMA US
ASTRAZENECA
ATRIX LABORATORIES
BAVARIAN NORDIC A/S
BAYER HEALTHCARE PHARMACEUTICALS
BRISTOL-MYERS SQUIBB
C.R. BARD
CZ BIOMED CORP.
DENDREON CORP.
DIAGNOCURE
EXELIXIS
GE HEALTHCARE
GENOMIC HEALTH
GLAXOSMITHKLINE
HOLOGIC
INTUITIVE SURGICAL
JOHNSON & JOHNSON
MEDIVATION
MILLENNIUM PHARMACEUTICALS
MYRIAD GENETICS
NORTHWEST BIOTHERAPEUTICS

16. ONCOGENEX
OPKO HEALTH
PFIZER
SANOFI
SIEMENS AG
SPECTRUM PHARMACEUTICALS
VARIAN MEDICAL SYSTEMS
Chapter - 15: REFERENCES
LIST OF TABLES
Summary Table: GLOBAL PROSTATE CANCER MARKET, THROUGH 2017
Table 1: U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS, 2008
Table 2: GROWTH FACTORS IMPLICATED IN PROSTATE CANCER
Table 3: PROPOSED PROSTATE CANCER SUSCEPTIBILITY LOCI
Table 4: IMPORTANT GENES IN THE DEVELOPMENT OF PROSTATE CANCER
Table 5: MUTATED GENES AND ABNORMAL PROTEIN EXPRESSION
Table 6: WHY PSA TESTING?
Table 7: PROSTATE CANCER: MAJOR POINTS
Table 8: ACS RECOMMENDATIONS FOR THE EARLY DETECTION OF CANCER IN
AVERAGE-RISK, ASYMPTOMATIC INDIVIDUALS
Table 9: PSA TEST: WHY AND WHEN?
Table 10: AGE-SPECIFIC REFERENCE RANGES FOR SERUM PSA
Table 11: OTHER CAUSES OF CHANGES IN PSA LEVEL
Table 12: IMPROVEMENTS TO THE PSA TEST
Table 13: PROSTATE CANCER: DIAGNOSIS AND TREATMENT STRATEGY
Table 14: PROSTATE CANCER TESTS
Table 15: TREATMENT OPTIONS FOR PROSTATE CANCER
Table 16: FACTORS FOR PROSTATE CANCER TREATMENT PLANNING
Table 17: GUIDE TO PROSTATE CANCER DIAGNOSIS AND MANAGEMENT
Table 18: TYPES OF SURGERY
Table 19: ADVANTAGES AND DISADVANTAGES OF RADICAL PROSTATECTOMY
Table 20: ADVANTAGES AND DISADVANTAGES OF INTERSTITIAL BRACHYTHERAPY
Table 21: ADVANTAGES AND DISADVANTAGES OF EXTERNAL BEAM RADIOTHERAPY
Table 22: ADVANTAGES AND DISADVANTAGES OF CRYOTHERAPY
Table 23: ADVANTAGES AND DISADVANTAGES OF ULTRASOUND
Table 24: HORMONE THERAPY
Table 25: STAGE I PROSTATE CANCER
Table 26: STAGE II PROSTATE CANCER
Table 27: STAGE III PROSTATE CANCER
Table 28: STAGE IV PROSTATE CANCER
Table 29: THERAPEUTICS FOR PROSTATE CANCER TREATMENT
Table 30: APPROVED FDA PROSTATE CANCER DRUGS
Table 31: COMMON DRUGS FOR TREATMENT OF PROSTATE CANCER

17. Table 32: THERAPEUTIC AGENTS FOR PROSTATE CANCER UNDER CLINICAL
DEVELOPMENT
Table 33: GLOBAL CANCER INCIDENCE ESTIMATES, 2008
Table 34: PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008
Table 35: GLOBAL ESTIMATED PROSTATE CANCER DEATHS: AGE-STANDARDIZED
MORTALITY RATES PER 100,000 MEN, 2008
Table 36: GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER, 2008-2030
Table 37: PROSTATE CANCER CASES AND DEATHS IN THE U.S., 2008 - 2011
Table 38: ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012 - 2030
Table 39: INCIDENCE RATES BY RACE IN THE U.S., 2005-2009
Table 40: ESTIMATED NEW PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030
Table 41: MORTALITY RATES BY RACE IN THE U.S., 2005-2009
Table 42: DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS
FOR MALES OF ALL RACES, 2002-2008
Table 43: RELATIVE SURVIVAL RATE FOR PROSTATE CANCER PATIENTS
Table 44: FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT THE TIME OF DIAGNOSIS
Table 45: ESTIMATED PROSTATE CANCER IN CANADA, 2012
Table 46: ESTIMATED PROSTATE CANCER MORTALITY IN EU27 COUNTRIES: AGE-
STANDARDIZED MORTALITY RATES PER 100,000 MEN, 2008
Table 47: PROSTATE CANCER DEATHS IN THE U.K., RATE PER 100,000 PEOPLE, 2010
Table 48: TYPE OF DIAGNOSTIC TESTS
Table 49: GLOBAL PSA TEST SALES AND FORECAST, THROUGH 2017
Table 50: U.S. PSA TEST SALES AND FORECAST, THROUGH 2017
Table 51: EUROPEAN PSA TEST SALES AND FORECAST, THROUGH 2017
Table 52: CANADIAN PSA TEST SALES AND FORECAST, THROUGH 2017
Table 53: OTHER COUNTRIES: PSA TEST SALES AND FORECAST, THROUGH 2017
Table 54: GLOBAL DIGITAL RECTAL EXAMINATION SALES AND FORECAST, THROUGH
2017
Table 55: U.S. DIGITAL RECTAL EXAMINATION SALES AND FORECAST, THROUGH 2017
Table 56: DIGITAL RECTAL EXAMINATION SALES AND FORECAST FOR THE REST OF THE
WORLD (EXCLUDING THE U.S.), THROUGH 2017
Table 57: GLOBAL COST OF PROSTATE BIOPSIES, THROUGH 2017
Table 58: U.S. COST OF PROSTATE BIOPSIES, THROUGH 2017
Table 59: COST OF PROSTATE BIOPSIES IN THE REST OF THE WORLD (EXCLUDING THE
U.S.), THROUGH 2017
Table 60: GLOBAL COSTS AND FORECAST FOR PROSTATE BIOPSIES BY REGION,
THROUGH 2017
Table 61: GLOBAL PROSTATE CANCER SCREENING SALES AND FORECAST, THROUGH
2017
Table 62: MANUFACTURERS/SUPPLIERS OF PROSTATE CANCER DIAGNOSTICS MARKET
SHARE, 2012
Table 63: LIST OF AVAILABLE PROSTATE NOMOGRAMS

18. Table 64: GLOBAL MARKET SIZE FOR IMAGING TECHNOLOGIES, THROUGH 2017
Table 65: MANUFACTURERS/SUPPLIERS OF PROSTATE CANCER IMAGING DEVICES
MARKET SHARE, 2012
Table 66: COST OF THE THREE LEADING PROSTATE CANCER THERAPIES, 2012
Table 67: SURGICAL DEVICE COMPANIES: KEY PLAYERS
Table 68: GLOBAL PROSTATE CANCER THERAPY MARKET: SALES AND FORECAST,
THROUGH 2017
Table 69: GLOBAL MARKET FOR EXTERNAL BEAM RADIATION THERAPY: FORECAST AND
SALES, 2010 - 2017
Table 70: GLOBAL BRACHYTHERAPY MARKET: FORECAST AND SALES, THROUGH 2017
Table 71: GLOBAL INCIDENCE OF PROSTATE CANCER, THROUGH 2017
Table 72: GLOBAL CASES OF PROSTATE SURGERIES PERFORMED PER YEAR, 2009 - 2017
Table 73: GLOBAL MARKET FOR PROSTATE SURGERIES: SALES AND FORECAST,
THROUGH 2017
Table 74: GLOBAL CASES OF ROBOTIC PROSTATECTOMIES PERFORMED PER YEAR,
2009 - 2017
Table 75: GLOBAL MARKET FOR ROBOTIC PROSTATECTOMY: SALES AND FORECAST,
THROUGH 2017
Table 76: GLOBAL MARKET FOR OPEN PROSTATECTOMY: SURGERIES PER YEAR,
THROUGH 2017
Table 77: GLOBAL MARKET FOR OPEN PROSTATECTOMY: SALES AND FORECAST,
THROUGH 2017
Table 78: U.S. UROLOGICAL DEVICE MARKET: SALES AND FORECAST, THROUGH 2017
Table 79: U.S. BRACHYTHERAPY MARKET: SALES AND FORECAST, THROUGH 2017
Table 80: PROSTATE CANCER INCIDENCE IN THE U.S., 2008 - 2017
Table 81: U.S. ROBOTIC PROSTATECTOMY MARKET: SALES AND FORECAST, THROUGH
2017
Table 82: PROSTATECTOMY SURGERIES PERFORMED EACH YEAR IN THE U.S., 2009 -
2017
Table 83: U.S. PROSTATECTOMY MARKET: SALES AND FORECAST, THROUGH 2017
Table 84: GLOBAL CANCER MARKET, THROUGH 2017
Table 85: GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017
Table 86: CYTOTOXIC THERAPIES MARKET INDICATIONS
Table 87: EXPIRY OF PATENTS ON MAJOR CYTOTOXIC DRUGS
Table 88: U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2017
Table 89: EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2017
Table 90: JAPANESE CYTOTHERAPEUTICS MARKET, THROUGH 2017
Table 91: MAJOR CYTOTOXIC BRANDS SALES, 2011
Table 92: PROSTATE CANCER: DRUG PRODUCTS AND TREATMENT MARKET, THROUGH
2017
Table 93: PROSTATE CANCER DRUG MARKET, THROUGH 2017
Table 94: PROSTATE CANCER DRUG PRODUCTS BY TREATMENT CATEGORY, THROUGH

19. 2017
Table 95: U.S. PROSTATE CANCER MARKET: PATIENTS AND TREATMENT STRATEGIES
Table 96: NEW DRUGS AND SALES FORECAST, 2017
Table 97: GLOBAL SALES AND FORECAST: KEY PROSTATE CANCER DRUGS, 2010 - 2012
Table 98: GLOBAL PROSTATE CANCER CHEMOTHERAPY DRUGS
Table 99: GLOBAL CHEMOTHERAPY MARKET FOR PROSTATE CANCER SALES AND
FORECAST, THROUGH 2017
Table 100: KEY CHEMOTHERAPEUTIC DRUGS FOR PROSTATE CANCER: SALES AND
FORECAST, 2010 - 2012
Table 101: GLOBAL PROSTATE CANCER HORMONAL THERAPY DRUGS
Table 102: HORMONE THERAPY FOR PROSTATE CANCER SALES AND FORECAST,
THROUGH 2017
Table 103: GENERICS: SALES AND FORECAST, THROUGH 2017
Table 104: CASODEX SALES AND FORECAST, THROUGH 2017
Table 105: ZYTIGA: SALES ESTIMATES FOR 2011 AND 2012
Table 106: GLOBAL SALES AND FORECAST FOR ZYTIGA, 2011 - 2017
Table 107: GLOBAL MARKET FOR FLUTAMIDE, 2009 AND 2010
Table 108: GLOBAL MARKET FOR TRIPTORELIN, 2009 AND 2010
Table 109: GLOBAL MARKET FOR LEUPROLIDE ACETATE, 2009 AND 2010
Table 110: GLOBAL MARKET FOR ZOLADEX: SALES AND FORECAST, 2009 - 2017
Table 111: GLOBAL PROSTATE CANCER IMMUNOTHERAPY DRUG SALES AND FORECAST,
THROUGH 2017
Table 112: PROVENGE ANNUAL SALES AND FORECAST, 2010 - 2017
Table 113: GLOBAL MARKET FOR PROSTATE CANCER BY REGION, THROUGH 2017
Table 114: PROSTATE CANCER CARE MARKET IN EUROPE, THROUGH 2017
Table 115: U.S. PROSTATE CANCER CARE MARKET, THROUGH 2017
Table 116: PROSTATE CANCER CARE MARKET IN CANADA, THROUGH 2017
Table 117: GLOBAL PROSTATE CANCER MARKET: SALES AND FORECAST, THROUGH
2017
Table 118: EMERGING PRODUCTS FOR PROSTATE CANCER
Table 119: PROSTATE CANCER PATENT TRENDS, 2002-2011
Table 120: PATENTS BY TREATMENT CATEGORY, 2002 - 2011
Table 121: EXPIRY OF PATENTS ON MAJOR BRANDS
Table 122: LIST OF KEY DENDREON PATENTS AND PATENT APPLICATIONS
LIST OF FIGURES
Summary Figure: GLOBAL PROSTATE CANCER MARKET, 2010 - 2017
Figure SAMPLE FIGURE: GLOBAL PROSTATE CANCER MARKET, 2010 - 2017
Figure 1: STRUCTURE OF CASODEX
Figure 2: CHEMICAL STRUCTURE OF ZOLADEX
Figure 3: CHEMICAL STRUCTURE OF ELIGARD
Figure 4: CHEMICAL STRUCTURE OF NILANDRON
Figure 5: CHEMICAL STRUCTURE OF FLUTAMIDE

20. Figure 6: CHEMICAL STRUCTURE OF TRELSTAR
Figure 7: CHEMICAL STRUCTURE OF ESTRAMUSTINE
Figure 8: CHEMICAL STRUCTURE OF FIRMAGON
Figure 9: CHEMICAL STRUCTURE OF DOCETAXEL
Figure 10: CHEMICAL STRUCTURE OF JEVTANA
Figure 11: CHEMICAL STRUCTURE OF ZYTIGA
Figure 12: GLOBAL CANCER INCIDENCE ESTIMATES, 2008
Figure 13: PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008
Figure 14: GLOBAL ESTIMATED PROSTATE CANCER DEATHS: AGE-STANDARDIZED
MORTALITY RATES PER 100,000 MEN, 2008
Figure 15: GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER 2008-2030
Figure 16: PROSTATE CANCER CASES AND DEATHS IN THE U.S., 2008 - 2011
Figure 17: ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012 - 2030
Figure 18: ESTIMATED NEW PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030
Figure 19: ESTIMATED PROSTATE CANCER MORTALITY IN EU27 COUNTRIES: AGE-
STANDARDIZED MORTALITY RATES PER 100,000 MEN, 2008
Figure 20: PROSTATE CANCER DEATHS IN THE U.K.: RATE PER 100,000 PEOPLE, 2010
Figure 21: GLOBAL PSA TEST SALES AND FORECAST, 2010 - 2017
Figure 22: U.S. PSA TEST SALES AND FORECAST, 2011 - 2017
Figure 23: EUROPEAN PSA TEST SALES AND FORECAST, 2011 - 2017
Figure 24: CANADIAN PSA TEST SALES AND FORECAST, 2011 - 2017
Figure 25: OTHER COUNTRIES: PSA TEST SALES AND FORECAST, 2010 - 2017
Figure 26: GLOBAL DIGITAL RECTAL EXAMINATION SALES AND FORECAST, 2010 - 2017
Figure 27: U.S. DIGITAL RECTAL EXAMINATION SALES AND FORECAST, 2010 - 2017
Figure 28: DIGITAL RECTAL EXAMINATION SALES AND FORECAST FOR THE REST OF THE
WORLD (EXCLUDING THE U.S.), 2010 - 2017
Figure 29: GLOBAL COST OF PROSTATE BIOPSIES, 2010 - 2017
Figure 30: U.S. COST OF PROSTATE BIOPSIES, 2010 - 2017
Figure 31: COST OF PROSTATE BIOPSIES IN THE REST OF THE WORLD (EXCLUDING THE
U.S.), 2010 - 2017
Figure 32: GLOBAL COSTS AND FORECAST FOR PROSTATE BIOPSIES BY REGION, 2010 -
2017
Figure 33: GLOBAL PROSTATE CANCER SCREENING SALES AND FORECAST, 2010 - 2017
Figure 34: GLOBAL MARKET SIZE FOR IMAGING TECHNOLOGIES, 2010 - 2017
Figure 35: GLOBAL PROSTATE CANCER THERAPY MARKET: SALES AND FORECAST, 2010
- 2017
Figure 36: GLOBAL MARKET FOR EXTERNAL BEAM RADIATION THERAPY: FORECAST AND
SALES, 2010 - 2017
Figure 37: GLOBAL BRACHYTHERAPY MARKET: FORECAST AND SALES, 2010 - 2017
Figure 38: GLOBAL INCIDENCE OF PROSTATE CANCER, 2008 - 2017
Figure 39: GLOBAL CASES OF PROSTATE SURGERIES PERFORMED PER YEAR, 2009 -
2017

21. Figure 40: GLOBAL MARKET FOR PROSTATE SURGERIES: SALES AND FORECAST, 2009 -
2017
Figure 41: GLOBAL MARKET FOR PROSTATE SURGERIES: SALES AND FORECAST, 2009-
2017
Figure 42: GLOBAL MARKET FOR ROBOTIC PROSTATECTOMY: SALES AND FORECAST,
2009 - 2017
Figure 43: GLOBAL MARKET FOR OPEN PROSTATECTOMY: SURGERIES PER YEAR, 2009 -
2017
Figure 44: GLOBAL MARKET FOR OPEN PROSTATECTOMY: SALES AND FORECAST, 2009 -
2017
Figure 45: U.S. UROLOGICAL DEVICE MARKET: SALES AND FORECAST, 2009 - 2017
Figure 46: U.S. BRACHYTHERAPY MARKET: SALES AND FORECAST, 2010 - 2017
Figure 47: PROSTATE CANCER INCIDENCE IN THE U.S., 2008 - 2017
Figure 48: U.S. ROBOTIC PROSTATECTOMY MARKET: SALES AND FORECAST, 2009 - 2017
Figure 49: PROSTATECTOMY SURGERIES PERFORMED EACH YEAR IN THE U.S., 2009 -
2017
Figure 50: U.S. PROSTATECTOMY MARKET: SALES AND FORECAST, 2009 - 2017
Figure 51: GLOBAL CANCER MARKET, 2010 - 2017
Figure 52: U.S. CYTOTHERAPEUTICS MARKET, 2010 - 2017
Figure 53: EUROPEAN CYTOTHERAPEUTICS MARKET, 2010 - 2017
Figure 54: JAPANESE CYTOTHERAPEUTICS MARKET, 2010 - 2017
Figure 55: PROSTATE CANCER: DRUG PRODUCTS AND TREATMENT MARKET, 2010 - 2017
Figure 56: PROSTATE CANCER DRUG MARKET, 2010 - 2017
Figure 57: PROSTATE CANCER DRUG PRODUCTS BY TREATMENT CATEGORY, 2010 - 2017
Figure 58: GLOBAL CHEMOTHERAPY MARKET FOR PROSTATE CANCER SALES AND
FORECAST, 2010 - 2017
Figure 59: HORMONE THERAPY FOR PROSTATE CANCER SALES AND FORECAST, 2010 -
2017
Figure 60: CASODEX SALES AND FORECAST, 2011-2017
Figure 61: ZYTIGA: SALES ESTIMATES FOR 2011 AND 2012
Figure 62: GLOBAL SALES AND FORECAST FOR ZYTIGA, 2011 - 2017
Figure 63: GLOBAL MARKET FOR ZOLADEX: SALES AND FORECAST, 2009 - 2017
Figure 64: GLOBAL PROSTATE CANCER IMMUNOTHERAPY DRUG SALES AND FORECAST,
2010 - 2017
Figure 65: PROVENGE ANNUAL SALES AND FORECAST, 2010 - 2017
Figure 66: GLOBAL MARKET FOR PROSTATE CANCER BY REGION, 2012 AND 2017
Figure 67: PROSTATE CANCER CARE MARKET IN EUROPE, 2012 AND 2017
Figure 68: U.S. PROSTATE CANCER CARE MARKET, 2012 AND 2017
Figure 69: PROSTATE CANCER CARE MARKET IN CANADA, 2012 AND 2017
Figure 70: GLOBAL PROSTATE CANCER MARKET: SALES AND FORECAST, 2010 - 2017

22. Contact: sales@reportsandreports.com for more information.